Form 4: Solid Biosciences Director Clare Kahn Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Director Clare Kahn of Solid Biosciences Inc. reports the acquisition and disposal of common stock on March 11, 2025.
Summary
- On March 11, 2025, Clare Kahn, a director of Solid Biosciences Inc., engaged in transactions involving the company's common stock.
- Kahn acquired 1,860 shares of common stock at a price of $5.3357 per share.
- Kahn also disposed of 2,960 shares of common stock.
- Following these transactions, the reported amount of securities beneficially owned by Kahn changed.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company director, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities.
Stakeholder Impact
- Shareholders are informed about the trading activities of a company director, which can influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/11/2025 | Date of stock transaction (acquisition and disposal). |
| 03/13/2025 | Date of signature on the report. |
Keywords
Solid Biosciences, SLDB, Form 4, Beneficial Ownership, Director, Clare Kahn, Stock Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.